TW279866B - - Google Patents

Info

Publication number
TW279866B
TW279866B TW083104441A TW83104441A TW279866B TW 279866 B TW279866 B TW 279866B TW 083104441 A TW083104441 A TW 083104441A TW 83104441 A TW83104441 A TW 83104441A TW 279866 B TW279866 B TW 279866B
Authority
TW
Taiwan
Application number
TW083104441A
Other languages
Chinese (zh)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of TW279866B publication Critical patent/TW279866B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW083104441A 1993-05-21 1994-05-17 TW279866B (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939310635A GB9310635D0 (en) 1993-05-21 1993-05-21 Chemical compounds

Publications (1)

Publication Number Publication Date
TW279866B true TW279866B (enExample) 1996-07-01

Family

ID=10736007

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083104441A TW279866B (enExample) 1993-05-21 1994-05-17

Country Status (19)

Country Link
EP (1) EP0699196A1 (enExample)
JP (1) JPH08510455A (enExample)
CN (1) CN1126473A (enExample)
AU (1) AU6928794A (enExample)
BG (1) BG100154A (enExample)
CA (1) CA2162921A1 (enExample)
CZ (1) CZ305195A3 (enExample)
FI (1) FI955587A7 (enExample)
GB (1) GB9310635D0 (enExample)
HU (1) HUT73790A (enExample)
IL (1) IL109703A0 (enExample)
NO (1) NO954681L (enExample)
OA (1) OA10195A (enExample)
PE (1) PE31195A1 (enExample)
PL (1) PL311702A1 (enExample)
SK (1) SK142495A3 (enExample)
TW (1) TW279866B (enExample)
WO (1) WO1994027989A1 (enExample)
ZA (1) ZA943494B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721943A4 (en) * 1993-09-30 1996-09-04 Yamanouchi Pharma Co Ltd AZOL DERIVATIVES AND PHARMACEUTICAL PREPARATIONS
WO1996014090A1 (en) * 1994-11-07 1996-05-17 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
NZ302392A (en) * 1995-03-01 1998-08-26 Yamanouchi Pharma Co Ltd Tricyclic substituted imidazole derivatives and medicaments thereof
CN1251577A (zh) * 1997-02-21 2000-04-26 武田药品工业株式会社 稠环化合物及其生产和应用
CA2429133C (en) 2000-11-17 2009-08-18 Takeda Chemical Industries, Ltd. Novel imidazole derivatives, production method thereof and use thereof
DE60144246D1 (de) 2000-11-20 2011-04-28 Takeda Pharmaceutical Imidazolderivate, verfahren zu deren herstellung und deren verwendung
WO2002046186A1 (en) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
AU2006262283B2 (en) * 2005-06-24 2011-10-13 Eli Lilly And Company Tetrahydrocarbazole derivatives useful as androgen receptor modulators (SARM)
GB0525323D0 (en) 2005-12-13 2006-01-18 Sterix Ltd Compound
US8093279B2 (en) 2005-12-13 2012-01-10 Gillian Reed, legal representative Compound
CN100586932C (zh) * 2007-01-26 2010-02-03 中国医学科学院医药生物技术研究所 抗肿瘤化合物及其制备方法
PE20121048A1 (es) 2009-06-26 2012-08-25 Novartis Ag Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
JP5964756B2 (ja) * 2010-02-04 2016-08-03 ラジウス ヘルス,インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
PL2568806T3 (pl) 2010-05-12 2017-03-31 Radius Health, Inc. Schematy lecznicze
KR101594660B1 (ko) 2010-08-04 2016-02-16 펠피큐어 파마슈티걸즈 아이엔씨 전립선 암종의 치료를 위한 병용 요법
EP2627648A1 (en) 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
MX359399B (es) 2011-04-28 2018-09-27 Novartis Ag Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
AU2014241816B9 (en) 2013-03-14 2019-02-14 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
WO2016040896A1 (en) 2014-09-12 2016-03-17 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
WO2017223115A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
WO2018080933A1 (en) 2016-10-24 2018-05-03 Pellficure Pharmaceuticals Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS229934B2 (en) * 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
GB8518743D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds

Also Published As

Publication number Publication date
NO954681D0 (no) 1995-11-20
PE31195A1 (es) 1995-10-18
FI955587A0 (fi) 1995-11-20
IL109703A0 (en) 1994-08-26
WO1994027989A1 (en) 1994-12-08
NO954681L (no) 1995-11-20
CZ305195A3 (en) 1996-06-12
OA10195A (en) 1996-12-18
AU6928794A (en) 1994-12-20
HUT73790A (en) 1996-09-30
PL311702A1 (en) 1996-03-04
CA2162921A1 (en) 1994-12-08
JPH08510455A (ja) 1996-11-05
ZA943494B (en) 1995-01-23
FI955587A7 (fi) 1995-11-20
EP0699196A1 (en) 1996-03-06
GB9310635D0 (en) 1993-07-07
BG100154A (en) 1996-07-31
SK142495A3 (en) 1996-06-05
CN1126473A (zh) 1996-07-10
HU9503321D0 (en) 1996-01-29

Similar Documents

Publication Publication Date Title
IN184938B (enExample)
EP0714291A4 (enExample)
DK0605845T3 (enExample)
DK0649622T3 (enExample)
TW249295B (enExample)
DK0618680T3 (enExample)
TW260662B (enExample)
EP0674978A4 (enExample)
DK63994A (enExample)
DK76793D0 (enExample)
EP0647920A3 (enExample)
DK69093D0 (enExample)
AU636285B1 (enExample)
DK24593D0 (enExample)
IN185940B (enExample)
TW236639B (enExample)
TW278163B (enExample)
ECSDI930157S (enExample)
IN177795B (enExample)
ECSMU930019U (enExample)
DK122793D0 (enExample)
ECSDI930173S (enExample)
IN181200B (enExample)
ECSDI930112S (enExample)
DK128793D0 (enExample)